home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  September 30, 2016
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 689 active entries

MOLOGEN AG

Fabeckstrasse 30
14195 Berlin
Germany

Phone: +49 30 84 17 88 0
Fax: +49 30 84 17 88 50

E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Stock symbol: MGN.FSE
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.

Description:

Company Overview:
MOLOGEN AG is a biopharmaceutical company located in Berlin and currently employs 44 people. The company specializes in the development of DNA-based therapeutics and vaccines against cancer and infectious diseases. The proprietary platform technologies MIDGE® and dSLIM® build the foundation for all business activities.
Founded in 1998, MOLOGEN was one of the first German biotechnology companies to go public. MOLOGEN AG shares are listed in the Prime Standard of Deutsche Börse (ISIN DE 0006637200).

Technologies:
Novel TLR9 Agonist dSLIM® (double Stem Loop ImmunoModulator): dumbbell-shaped molecule  with two single-stranded loops that are connected by a double-stranded stem, consisting of only non-coding DNA without any chemical modification; action of dSLIM® molecule is mediated through binding to TLR9 and results in a broad activation of the immune system initiating a fast defensive reaction against infectious agents;
dSLIM®-based cancer medicine MGN1703 (CRC) currently in phase I; phase II planned for Q4/2009

MIDGE® (Minimalistic Immunogenically Defined Gene Expression): DNA-vector that exclusively contains the clinically relevant genetic information; MIDGE® features a linear DNA pattern and is covalently closed by single-stranded hairpin structures at both ends; hairpin tails may be attached with different molecules allowing for various applications (e.g. MIDGE®-Th1 vector induces improved cellular and humoral immune responses, therefore it is well suited for DNA vaccination);
preclinical development of MGN1331, a DNA vaccine against human Leishmaniasis, funded by the 7th Research Framework Programme of the EU   

For more information about the company or the current status of development programs please visit: www.mologen.com



Selected Categories:
Product Company   Service Company
Biotech
- Research

Last update of this entry: July 20, 2009

Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.